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1. Introduction 
All therapeutic interventions are double-edged swords with benefits and adverse effects, 
and pharmacotherapy is not an exception. Shortly after the introduction of conventional 
antipsychotic drugs into clinical practice, relatively rare but serious complications with 
hyperthermia, muscle rigidity, autonomic instability, and disturbed mental status were 
recognized to develop in some patients treated with antipsychotics. This type of 
encephalopathy induced by the use of antipsychotics was referred to as neuroleptic 
malignant syndrome (NMS), and almost all physicians prescribing antipsychotics are 
nowadays aware of this adverse phenomenon. Another well-known type of encephalopathy 
associated with psychotropic drug therapy is serotonin toxicity (ST) or serotonin syndrome 
(SS), which is characterized by autonomic and neuromuscular symptoms and altered mental 
status. In contrast with the idiosyncratic nature of NMS, ST is a spectrum 
pathophysiological state assumed to derive from excess serotonergic neural transmission 
caused by serotonin-related psychotropic agents. In these two decades, pharmacotherapy 
with psychotropic drugs for mentally ill patients has been dramatically changed, and 
classical prototypal antipsychotics and antidepressants have been replaced with atypical 
antipsychotics and selective serotonin reuptake inhibitors (SSRIs), respectively. These newly 
developed psychotropic drugs are generally safer and more tolerable than older drugs. 
However, atypical antipsychotics are not free of the risk of development of NMS, and the 
explosive prevalence of SSRIs prescribed not only for depression but also for a number of 
psychiatric diagnoses such as anxiety, eating, impulse-control, and personality disorders 
may increase the incidence of ST. Therefore, these two pathological states still remain as 
major adverse effects of psychotropic drugs involving altered functioning of the central 
nervous system (CNS), to which all clinicians prescribing psychoactive drugs should pay 
attention. The popularity of SSRIs also increased the case reports of patients suffering from 
discontinuation syndrome, which sometimes includes CNS symptoms like anxiety and 
irritability. In this chapter, the author provides a comprehensive overview of the above-
mentioned adverse effects affecting the CNS function associated with psychotropic 
pharmacotherapy. In addition, several other pathological conditions potentially causing 
encephalopathic symptoms in psychiatric patients treated with psychotropic drugs, e.g., 
hyponatremia, valproate-induced hyperammonemia, transient splenial lesion of the corpus 
callosum, and so on, are also described. 
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2. Neuroleptic malignant syndrome 
2.1 Historical background 
In the late 1950s, immediately after the introduction of antipsychotics into the clinical 
practice, single case reports of encephalopathic reaction to antipsychotic agents with fever, 
muscle rigidity, and autonomic dysfunction were already described (Kinross-Wright, 1958; 
Preston, 1959). In 1960s, French psychiatrists took notice of such cases and designated them as 
NMS (Delay & Deniker, 1968). However, the syndrome had been thereafter reported only 
occasionally and little attention had been paid to the concept of NMS, especially in the United 
States, until Caroff (1980) reviewed 60 cases of NMS reported in the scientific literature to that 
time. His review article renewed interest of clinicians and researchers all over the world and 
proliferated the reports on the epidemiology, risk factors, symptomatology, diagnostic criteria, 
differential diagnoses, pathophysiology, and treatment of the syndrome. At the present time, 
NMS is one of the most popularly recognized complications of psychotropic pharmacotherapy 
and described in most standard medical textbooks. 
2.2 Epidemiology 
Along with an increase in awareness of its concept after the Caroff’s review (1980), many 
patients diagnosed as NMS were reported throughout the world and it was recognized that 
NMS was not so rare than formerly supposed. In the review by Keck et al. (1991) on the 
epidemiology of NMS, the estimated frequency of NMS was reported to be within a wide 
range from 0.02 % to 2.4 %. The high incidence of NMS reported in earlier studies from the 
United States is, however, evidently overestimated due to a variety of factors, e.g., 
retrospective study design, loose diagnostic criteria, adherence to an amorphous “spectrum 
concept”, and clinical practices in vogue (Adityanjee et al., 1999a). Based on the more recent 
reports (Spivak et al., 2000; Montoya et al., 2003; Shiloh et al., 2003) as well as my own 
clinical experience as a psychiatrist at the front for almost three decades, the incidence of 
definite NMS does not appear to exceed 2-3 cases out of one thousand consecutive patients 
treated with antipsychotics, as long as precautionary measures and monitoring are 
cautiously and sufficiently employed for the early recognition and prevention of NMS. 
2.3 Clinical features 
The principal clinical manifestations of NMS are characterized by the symptoms related to 
the following 4 major areas: (1) hyperpyrexia, (2) extrapyramidal symptoms (EPS), (3) 
altered mental status, and (4) autonomic instability. Hyperthermia is prerequisite to being 
diagnosed as NMS (Kurlan et al., 1984; Levenson, 1985; Addonizio et al., 1987; Caroff & 
Mann., 1988; Rosebush & Stewart, 1989), with a body temperature exceeding 38 ºC in most 
cases, and as high as 40-41 ºC in some patients. The EPS are also noted in almost all cases 
reported as NMS, typically represented as muscle rigidity accompanied by tremors, which is 
often described as “lead-pipe” or “plastic”. Other forms of EPS including focal dystonia, 
sialorrhea, dysphagia, dysarthria, opisthotonus, oculogyric crisis, chorea and dyskinesia are 
sometimes observed as accompanying symptoms. Altered mental status includes varied 
levels of consciousness disturbances ranging from drowsiness to coma, confusion, agitation, 
delirium, stupor, mutism and so on. Involvement of the autonomic system is manifested by 
severe tachycardia, labile blood pressure, profuse diaphoresis, dyspnea and incontinence.  
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Although laboratory abnormalities of NMS are nonspecific, elevation of serum creatine 
phosphokinase (CPK) (>99 % derived from muscle fraction) is noted in almost all cases, 
which reflects significant muscle damage during development of NMS. In severely affected 
cases, it often exceeds 10,000 IU/liter with a high risk of development of myoglobinuria and 
renal failure. Leukocytosis is also seen in almost all patients with NMS. Hepatic enzymes are 
occasionally elevated but less dramatically than CPK. 
Diagnosis of NMS is made based on the above-mentioned clinical symptoms and laboratory 
findings when these abnormalities develop subsequent to the initiation of or increase in 
antipsychotics and other medical conditions can be excluded. The typical cases with “full-
blown” symptoms appear to be diagnosed with ease if the physician is aware of the concept 
of NMS. Several diagnostic criteria for NMS have been proposed by different researchers 
(Levenson, 1985; Addonizio et al., 1986; Pope et al., 1986; Adityanjee et al., 1988; J.H. 
Friedman et al., 1988; Keck et al., 1989a, 1989b; Caroff et al., 1991; Nierenberg et al., 1991; 
Caroff & Mann, 1993; Adityanjee et al., 1999b), and here presented in Table 1 is the research 
criteria for NMS described in DSM-IV-TR (Frances et al., 2000). 
A. The development of severe muscle rigidity and elevated temperature associated 
with the use of neuroleptic medication. 
B. Two (or more) of the following: 
 (1) diaphoresis 
 (2) dysphagia 
 (3) tremor 
 (4) incontinence 
 (5) changes in level of consciousness ranging from confusion to coma 
 (6) mutism 
 (7) tachycardia 
 (8) elevated or labile blood pressure 
 (9) leucocytosis 
 (10) laboratory evidence of muscle injury (e.g., elevated CPK) 
C. The symptoms in Criteria A and B are not due to another substance (e.g., 
phencyclidine) or a neurological or other general medical condition (e.g., viral 
encephalitis). 
D. The symptoms in Criteria A and B are not better accounted for by a mental disorder 
(e.g., Mood Disorder With Catatonic Features). 
Table 1. Research criteria for NMS described in DSM-IV (Frances et al., 2000) 
2.4 Precipitating agents 
Virtually all classes of dopamine D2 receptor antagonists have been associated with NMS. 
This includes not only neuroleptics in a narrow sense (either typical or atypical 
antipsychotics) prescribed for the control of psychotic symptoms, but also several classes of 
drugs with the potential to block D2 receptors in CNS used as antidepressants, antiemetics, 
anesthetics, and sedatives (e.g., Robinson et al, 1985; L.S. Friedman et al., 1987; Taylor & 
Schwartz, 1988; Madakasira, 1989; Spirt et al., 1992; Chan-Tack, 1999). 
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Aside from cases with NMS associated with the use of antagonists for dopamine D2 
receptors, the clinical features identical or closely resemblant to NMS have been occasionally 
reported to develop during the course of the treatment with antiparkinsonian drugs, 
especially after the withdrawal or reduction of them, in patients with Parkinson’s disease 
(Henderson & Wooten, 1981; Toru et al., 1981; J.H. Friedman et al., 1985; Y. Yamawaki & 
Ogawa, 1992; Serrano-Dueňas, 2003; Takubo et al., 2003). In these cases, it may be 
inappropriate to use the term NMS since the patients were not receiving “neuroleptics” 
(Addonizio et al., 1987), and some strict researchers refer to such cases as “NMS-like state” 
(Toru et al., 1981), “malignant dopaminergic syndrome” (Serrano-Dueňas, 2003), or simply 
as “malignant syndrome” (Takubo et al., 2003). Irrespective of how it is called, the 
underlying pathophysiology to precipitate the clinical course in these patients is supposed 
to be dopaminergic hypofunction in CNS, which is identical to that in the patients with 
NMS induced by the use of antipsychotics. Therefore, it appears acceptable to consider the 
episode fulfilling the clinical features of NMS in patients with Parkinson’s disease as a 
variant of NMS, even if it is not induced by the use of neuroleptics. 
The similar syndromes have also been reported to be caused by numerous other classes of 
drugs with different mechanisms of action [e.g., lithium, clomipramine, nortryptiline, SSRIs, 
benzodiazepines] (Kellam, 1987a; Ananth et al., 2004a, but see also Assion et al., 1998), and 
even in the absence of any pharmacotherapeutic intervention (the so-called lethal catatonia), 
and thus some researchers have commented that NMS is a misnomer (Singh & Maguire, 1987; 
Brennan et al., 1988). They proposed novel names such as “iatrogenic malignant syndrome” 
(Singh & Maguire, 1987) or “pyrexial catatonia” (Kellam, 1987b) instead of NMS. Heyland & 
Sauvé (1991) suggested a new label “drug-induced central hyperthermic syndrome” for such 
cases. In my opinion, however, these designations are too vague as a diagnosis in clinical 
settings, and it should be avoided to broaden the concept of NMS to too much extent. 
2.5 Risk factors 
As shown in Table 2, there had been many potential risk factors for NMS identified or 
postulated in numerous reviews, case series, and reports published until 1989 (Keck et al., 
1989a). Among them, demographic items such as sex, age, and psychiatric diagnosis are not 
of essential importance as risk factors (Caroff & Mann, 1993). It should be kept in mind that 
NMS can develop regardless of sex, age, and psychiatric diagnosis, when antipsychotic 
agents are administered to a patient. Case-controlled studies (Keck et al., 1989a; Berardi et 
al., 1998; Viejo et al., 2003) have indicated psychopathological features such as agitation, 
confusion, disorganized behavior, and catatonia, as well as pharmacological features such as 
higher neuroleptic dose at greater rates of dose increase and parenteral neuroleptic 
injections, as risk factors. It has been reported that antecedent existence of EPS including 
akathisia is also a risk factor of NMS (Berardi et al., 1998). NMS occurs independent of 
climate and ambient conditions (Caroff & Mann, 1993), and Viejo et al. (2003) were unable to 
find a significant difference in environmental temperature at onset of clinical symptoms of 
NMS between the cases and matched-controls. Considering various cases of NMS reported 
to develop during heat waves (Shalev et al., 1988; Fitzgerald et al., 1997), however, adverse 
climate conditions with high temperature and excessive humidity may be important in some 
cases to trigger the development of NMS. High serum CPK levels during psychotic episodes 
may also be a risk factor for NMS (Hermesh et al., 2002). 
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 Maximum dose of neuroleptic 
Rate of neuroleptic dose increase 
Neuroleptic potency 
Route of neuroleptic administration 
Concurrent administration of lithium salts 
Antecedent withdrawal of anticholinergic agents 
Antecedent withdrawal of dopamine agonists 
Medical status 
 Psychomotor agitation, exhaustion, or both 
Antecedent or concurrent medical illness 
Antecedent or concurrent neurological illness 
Recent history of alcohol or other substance abuse or dependence 
Thyrotoxicosis 
Environmental 
 Elevated ambient temperature 
Table 2. Risk factors for NMS identified or postulated until the report by Keck et al. (1989a) 
Familial occurrence of NMS has been reported occasionally (Deuschl et al., 1987; Otani et al., 
1991; Ziegenbein et al., 2006), suggesting that a predisposition to NMS is genetically 
governed in some cases. Extreme caution should be then paid to a patient with a family 
history of NMS, to whom it is necessary to initiate pharmacotherapy with antipsychotics. 
2.6 Clinical course and outcome 
Although the reported duration of exposure to antipsychotics prior to the development of 
NMS is extremely varied, the majority of cases occur within 1 to 2 weeks after the initiation 
of an offending drug (Shalev & Munitz, 1986; Addonizio et al., 1987; Caroff et al., 1988). 
Though nonspecific, the following signs and symptoms have been reported to precede NMS 
in some cases: unexpected changes in mental status, particularly obtundation or new-onset 
catatonia; episodic tachycardia, tachypnea, or hypertension; incontinence; low-grade 
temperature elevations; dysarthria, dysphagia, diaphoresis, sialorrhea, rigidity, myoclonus, 
tremor or other EPS unresponsive to antiparkinsonian agents; and unexplained elevation in 
serum CPK (Caroff et al., 1991; Caroff & Mann, 1993). Since almost all of these are 
themselves constituent symptoms of NMS (see above), it may be possible to diagnose a 
patient with such prodromal or early symptoms as NMS, depending on the diagnostic 
criteria of NMS adopted. At any rate, it is practically very important to be aware of 
sequential progression of symptoms of NMS in order to facilitate prompt recognition and 
interventions to abort the symptoms in its incipient stage. Analysis of the temporal sequence 
of the four predominant clinical features of NMS has indicated that either altered mental 
status or muscle rigidity precedes hyperthermia and autonomic dysfunction in the majority 
of fulminant NMS cases, most typically with the following order: (1) changes in mental 
status; (2) muscle rigidity; (3) hyperthermia; and (4) autonomic dysfunction (Velamoor et al., 
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1994). Woodbery & Woodbery (1992) proposed five discrete stages toward the progression 
of NMS, from stage I or drug-induced parkinsonism to stage V (the severest form of 
fulminant NMS). This spectrum-based concept of NMS (Fig. 1) may be practically useful to 
comprehend the progression of symptoms, at least in typical cases (Odagaki, 2009).  
 
Fig. 1. The typical progression of symptoms of NMS from the mildest stage I (drug-induced 
parkinsonism) through stage V or the severest form of NMS (Odagaki, 2009). Stages I-V are 
originally proposed by Woodbury and Woodbury (1992) and adapted by Strawn et al. 
(2007). 
Once antipsychotics are stopped, NMS is self-limited barring complications, with the 
duration to resolution of NMS up to two weeks in the majority of cases (Shalev & Munitz, 
1986; Addonizio et al., 1987; Caroff et al., 1988). The notion that prompt withdrawal of the 
offending agent at early stage can prevent progression to definite NMS has been 
corroborated by the study reported by Shiloh et al. (2003). 
The clinical course of NMS can be modified by concurrence of many complications. 
Although most medical problems are reported as complications (Addonizio et al., 1987), one 
of the most common and serious complications of NMS is acute renal failure caused by 
rhabdomyolysis (Levenson, 1985). As it has been reported that renal failure and 
myoglobinemia are associated with a significantly higher risk of mortality in NMS (Shalev et 
al., 1989), careful monitoring is necessary as to serum CPK levels, myoglobinemia 
/myoglobinuria, and renal functions throughout the course of NMS. As impressed with its 
designation, NMS is potentially lethal (Kellam, 1987a). The mortality rate was, however, 
reported even in the late 1980s to be apparently declined as compared with the former 
reports, and the overall rate of mortality for patients without concurrent organic diseases 
was reported as less than 10 % since 1984 (Shalev et al., 1989). The survey on NMS cases 
conducted in Japan also showed a clear chronological decline of mortality rate, which 
reached below 10 % in the latest years of the survey (S. Yamawaki et al., 1990). 
Although persistent, long-term clinical sequelae of NMS were historically considered rare, 
there have been substantial case reports with deficits related to complications or severity of 
the syndrome, particularly hypoxia or hyperthermia. As neuropsychiatric sequelae of NMS, 
Adityanjee et al. (2005) raised CNS dysfunctions manifested as cognitive impairment or as 
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parkinsonian syndrome, peripheral neurologic impairment such as peripheral neuropathy, 
and psychological impairment including severe depression. 
2.7 Differential diagnosis 
Differential diagnosis is of prime importance, because NMS constituted with nonspecific 
symptoms and laboratory abnormalities is a diagnosis of exclusion. The disorders listed in 
Table 3 (Strawn et al., 2007) should be considered as differential diagnoses.  
Infectious 
 Meningitis or encephalitis 
Postinfectious encephalomyelitis syndrome 
Brain abscess 
Sepsis 
Psychiatric or neurological 
 Idiopathic malignant catatonia 
Agitated delirium 
Benign extrapyramidal side effects 
Nonconvulsive status epileptics 
Structural lesions, particularly involving the midbrain 
Toxic or pharmacological 
 Anticholinergic delirium 
Salicylate poisoning 
Malignant hyperthermia (inhalational anesthetics, succinylcholine) 
Serotonin syndrome (monoamine oxidase inhibitors, triptans, linezolid) 
Substances of abuse (amphetamines, hallucinogens) 






Table 3. Differential diagnosis of NMS (Strawn et al., 2007) 
Among these, idiopathic malignant (lethal) catatonia and SS are of special importance from 
the practical as well as theoretical viewpoints. Idiopathic malignant catatonia, a life-
threatening febrile neuropsychiatric syndrome that had been described well several decades 
before the advent of antipsychotic drugs, is clinically quite similar to, and often 
indistinguishable from, NMS (Mann et al., 1986). Some researchers indeed regard NMS as a 
drug-induced iatrogenic form of malignant catatonia with the same underlying 
pathophysiology (Mann et al., 1986; White, 1992; Fink, 1996a; Carroll & Taylor, 1997; 
Fricchione et al., 2000). On the other hand, Castillo et al. (1989) emphasized the importance 
of differentiating these two syndromes clinically. In response to the editorial by Fink 
(1996a), Northhoff (1996) also contributed a correspondence against the notion that NMS 
and catatonia were variants of the same disorder. The similar debate has been held on the 
discrimination between NMS and SS (Fink, 1996b; Kontaxakis et al., 2003; Odagaki, 2009; 
Steele et al., 2011). It is beyond the scope of this article to have a detailed discussion on the 
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possibility that NMS belongs to a spectrum of the same disorder that contains catatonia 
and/or SS. Nevertheless, clinicians should keep an effort to differentiate NMS from other 
pathological conditions as long as there may be some differences in etiology, 
pathophysiology, and treatment. 
2.8 NMS associated with atypical antipsychotics 
With widespread use of atypical antipsychotics in recent years, NMS induced by these 
drugs has attracted much attention of clinicians and researchers (Caroff et al., 2000; Farver, 
2003; Ananth et al., 2004b; Trollor et al., 2009). At the same time, great interest has also been 
taken in the concept of “atypical NMS”, which is often presumed to be more associated with 
atypical antipsychotics than with conventional drugs (Picard et al., 2008). Though still 
controversial, the review of Trollor et al. (2009) suggests that NMS associated with atypical 
antipsychotics manifests in a typical manner, with one notable exception of clozapine-
induced NMS which appears to be less associated with EPS. It should be borne in mind that 
even the atypical antipsychotics have the potential to precipitate the patient to NMS, as long 
as they are dopamine D2 receptor antagonists. 
2.9 Pathophysiology 
Although the precise pathophysiological mechanisms underlying NMS are still unknown, 
antipsychotic-induced dopamine D2 receptor blockade in the striatum and hypothalamus 
likely plays a pivotal role, at least at its initial stages, for the development of NMS (Mann et 
al., 2000). In addition to dopaminergic dysfunction, complex alterations in functioning of 
different neurotransmitters in various brain regions, e.g., norepinephrine, serotonin, γ-
aminobutyric acid (GABA), and glutamate, are believed to be involved in the expression of 
multifarious clinical features of NMS (Ananth, 2004a). Through complex neurochemical as 
well as structural interactions among multiple neural transmission systems, a vicious circle 
likely develops to end a failure of homeostasis, irreversibly and lethal in some cases, that is 
involved in maintenance of consciousness and regulation of extrapyramidal motor function, 
body temperature, and autonomic functions. Especially in the fulminant cases with severe 
autonomic instability, uncoordinated hyperactivity of the peripheral sympathoadrenal 
systems, culminating in an end-stage hypermetabolic syndrome, is hypothesized (Feibel & 
Schiffer, 1981; Gurrera & Romero, 1992; Gurrera, 1999). 
2.10 Treatment 
One of the most important, and probably the most effective measures to avoid “malignant” 
sequence of the syndrome is a removal of the potentially offending drug(s) as prompt as 
possible. Although the treatment of NMS should be individualized for each patient 
depending on the clinical features and situations, the mainstay is good supportive medical 
care against extreme hyperthermia, dehydration, metabolic acidosis, nutritive and 
electrolyte imbalance, and occurrence of the complications including cardiorespiratory 
and/or renal failures, aspiration pneumonia, rhabdomyolysis, and coagulapathies. Several 
specific treatments recommended for management of NMS (Table 4) should be taken into 
consideration as additional therapeutic options, based on the severity and clinical course 
(Sakkas et al., 1991a, 1991b; Davis et al., 2000). However, it should be stressed that these 
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specific remedies for NMS are derived from empirical reports or theoretical grounds, rather 
than based on prospective, randomized controlled studies (Susman, 2001). For instance, 
conflicting results have been shown even about the usefulness of dantrolene and 
bromocriptine, the two most well established drugs for treatment of NMS (Rosenberg & 
Green, 1989; Rosebush et al., 1991; Reulbach et al., 2007). 
Treatment with Comments 
 Anticholinergics Still controversial, but may be useful in mild or early cases 
to help attenuate EPS (Woodbury and Woodbury, 1992) 
 Benzodiazepines May be useful when catatonic symptoms predominate 
(Francis et al., 2000) 
 Dopaminergic agonists  
  Bromocriptine One of the most well established pharmacologic agents for 
NMS (Rosenberg & Green, 1989; Sakkas et al., 1991a, 1991b) 
  Levodopa Successful cases reported (Harris et al., 1987; Sakkas et al., 
1991a; Nisijima et al., 1997) 
  Amantadine Its use associated with a statistically significant decrease in 
mortality (Sakkas et al., 1991a, 1991b) 
 Dantrolene One of the most well established pharmacologic agents for 
NMS (Rosenberg & Green, 1989; Sakkas et al., 1991a, 1991b) 
 Electroconvulsive 
therapy (ECT) 
Should be considered when pharmacotherapy has failed or 
when idiopathic malignant catatonia cannot be ruled out 
(Davis et al., 1991; Trollor & Sachdev, 1999) 
Table 4. Specific therapeutic remedies proposed for treatment of NMS 
3. Serotonin toxicity (serotonin syndrome) 
3.1 Historical background 
The term “serotonin syndrome (SS)” was originally derived from the experimental 
behavioral model in rodents (Jacobs, 1976; Gerson & Baldessarini, 1980), and introduced into 
clinical medicine in 1982 for the first time to describe the toxic reactions to the co-
administration of a monoamine oxidase inhibitor (MAOI) clorgyline and a tricyclic 
antidepressant (TCA) clomipramine in two obsessive-compulsive disorder patients (Insel et 
al., 1982). In fact, however, many similar case reports date back to 1950s (e.g., Mitchell, 
1955), the era of prevailing use of MAOIs such as isoniazid and iproniazid as 
antidepressants or antituberculous drugs (Gillman, 1998). The first review article on SS, 
based on the summary of 12 clinical reports between 1982 and 1990 (Sternbach, 1991), was 
instrumental in popularizing the syndrome to physicians, and awareness of SS as a distinct 
clinical entity increased the number of reported cases diagnosed as SS in the following two 
decades. 
As pointed out by Isbister & Buckley (2005), the term SS is often equivocally used and the 
clinical literature on this subject is sometimes inconsistent and confused. In the present 
article, the term “serotonin toxicity (ST)” is generally used to refer to the clinical state with 
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3.2 Clinical features and diagnosis 
According to the conventional definition based on relatively severe cases reported in the 
literature (Sternbach, 1991), SS can be described as a clinical triad of (1) mental-status 
changes, (2) autonomic hyperactivity, and (3) neuromuscular abnormalities. The diagnostic 
criteria for SS suggested by Sternbach (1991) are shown in Table 5. 
A. Coincident with the addition of or increase in a known serotonergic agent to an 
established medication regimen, at least three of the following clinical features are 
present: 
 1) mental status changes (confusion, hypomania) 
 2) agitation 
 3) myoclonus 
 4) hyperreflexia 
 5) diaphoresis 
 6) shivering 
 7) tremor 
 8) diarrhea 
 9) incoordination 
 10) fever 
B. Other etiologies (e.g., infectious, metabolic, substance abuse or withdrawal) have 
been ruled out. 
C. A neuroleptic had not been started or increased in dosage prior to the onset of the 
signs and symptoms listed above. 
Table 5. Suggested diagnostic criteria for SS (Sternbach, 1991) 
In practice, the signs and symptoms of ST range from tremor and diarrhea in mild cases to 
delirium, neuromuscular rigidity, and excessive hyperthermia in life-threatening cases, 
depending on the extent of serotonin excess. The clinical sequelae of serotonin excess are 
best thought of as a spectrum of toxicity, rather than a defined clinical entity (syndrome) 
with clear prognostic importance (Dunkley et al., 2003). Randomski et al. (2000) divided the 
cases into: (1) mild state of serotonin-related symptoms; (2) serotonin syndrome (full-blown 
form); and (3) toxic states (Fig. 2). 
 
Fig. 2. Spectrum concept of ST (Adapted from Boyer & Shannon, 2005), with three clinical 
stages designated by Radomski et al. (2000). 
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To assess the severity of ST, the scale developed by Hegerl et al. (1998) may be useful. When 
adapted to the depressed patients treated with paroxetine, it was positively correlated with 
paroxetine concentrations and inversely correlated with auditory evoked potential (an 
indirect measure of serotonergic activity). Their scale consists of the following nine items 
each rated from 0 to 3: agitation, disorders of orientation, myoclonus, hyperreflexia, tremor, 
dizziness, hyperthermia, sweating, and diarrhoea. 
Dunkley et al. (2003) analyzed the clinical data in 2222 consecutive cases of self-poisoning 
with serotonergic drugs, and found that several clinical features were associated with the 
diagnosis of SS. They developed the diagnostic decision rules for ST (Fig. 3), based on the 
results of their analysis as well as by including muscular hypertonicity and hyperthermia, 
both characteristic symptoms of the severe, life-threatening SS cases. 
The onset of symptoms is usually rapid, with clinical findings often occurring within 
minutes, and in most cases within 24 hours, after initial use, an overdose, or a change in 
dosing of the offending drug(s) (Mason et al., 2000). It should be noted that the syndrome is 
often misdiagnosed initially, especially as exacerbation of psychiatric disorder with anxiety 
or agitation (MacKay et al., 1999; Attar-Herzerg et al., 2009). Patients with mild 
manifestations may present with subacute or chronic symptoms, whereas severe cases may 
progress rapidly to death (Sporer, 1995; Boyer & Shannon, 2005). The most notorious 
example of such fatal patients is the ‘Libby Zion’ case (Asch & Parker, 1988). Other severe 
complications of SS include seizures, disseminated intravascular coagulation, respiratory 
failure, severe hyperthermia, ventricular arrhythmia, and rhabdomyolysis (Sporer, 1995). 
Milder cases show resolution of the symptoms typically within 24 hours once the offending 
agents are discontinued (Sternbach, 1991). 
 
Fig. 3. Diagnostic criteria for SS proposed by Dunkley et al. (2003). 
There are no confirmatory or specific laboratory tests available for the diagnosis of SS. 
Laboratory tests are best used to identify potential complications and assist in overall 
patient care. Elevated CPK has been reported in 18 % (Mills, 1997) or 34 % (Keck & Arnold, 
2000) of the cases, usually associated with muscle rigidity and rhabdomyolysis. 
Electroencephalograms (EEG) may show general slowing, consistent with diffuse 
encephalopathy (Mills, 1997). Highly abnormal EEG findings, such as (poly-)spikes and 
waves (Lejoyeux et al., 1992) and pronounced triphasic waves (Dike, 1997), were also 
reported in patients with SS. 
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3.3 Precipitating agents 
Virtually all medications that potentiate serononergic neurotransmission in the CNS have 
been reported in association with the cases of SS (Keck & Arnold, 2000), either alone or in 
combination. As shown in Table 6, the most common drug combinations causing the SS are 
MAOIs and antidepressants (SSRIs or TCAs) (Sporer, 1995). The severity of ST precipitated 
by the offending drug(s) is predictable well according to the serotonin levels measured in 
animal experiments (Gillman, 2006). The highest serotonin levels determined by 
microdialysis studies is achieved by the combination of MAOI and serotonin reuptake 
inhibitor (SRI) (100-fold as compared with baseline), followed by MAOI plus L-tryptophan 
(15-fold), MAOI alone (10-fold), moclobemide plus 3,4-methylenedioxymethamphetamine 
(MDMA) (10-fold), MDMA alone (5-fold), SSRI alone (3-fold), venlafaxine alone (3-fold), 
moclobemide alone (1.5-fold), TCA alone (1.25-fold), and mirtazapine alone (1.2-fold). 
Although mirtazapine alone stands at the lowest risk for ST, there has been a case report of 
severe SS induced by mirtazapine monotherapy (Hernández et al., 2002). 
Drug combination Number of cases 
 MAOI + Pethidine (Meperidine) 9  
 MAOI + Dextromethorphan 4  
 MAOI + Tryptophan 9  
 Reversible MAOI + TCA 2  
 Reversible MAOI + SSRI 5  
 MAOI-B + SSRI 6  
 MAOI-B + TCA 2  
 MAOI + SSRI 24  
 MAOI + TCA 16  
 SSRI + Dextromethorphan 1  
 SSRI + Tryptophan 5  
 SSRI + Lithium 1  
 SSRI + Pentazocine 1  
 Buspirone + Trazodone 1  
 TCA + Lithium 1  
 Bromocriptine + Levodopa 1  
 Phenelzine + Trazodone + Dextropropoxyphene 1  
 Clomipramine 1  
 MDMA 2  
 Fentanyl + Sertraline 1  
 Sertraline 1  
 Ademetionine (S-Adenosyl methionine) + Clomipramine 1  
Table 6. List of the agents reported to cause SS (Sporer, 1995) 
3.4 Differential diagnosis 
The differential diagnosis of SS involves disorders producing cognitive and behavioral, 
neuromuscular, and autonomic nervous system dysfunction with or without hyperthermia 
(Keck & Arnold, 2000), such as anticholinergic poisoning, malignant hyperthermia, and 
NMS (Boyer & Shannon, 2005). SS can be confused with NMS, particularly when both 
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serotonergic and neuroleptic drugs had been used concomitantly in a patient showing 
severe life-threatening symptoms and/or complications described before. The following 
features are raised by Gillman (1999) for differentiation between the two syndromes: 
NMS, slow onset (days to weeks) and slow progression over 24-72 hours in association 
with neuroleptics versus SS, both rapid onset and rapid progression (minutes to hours) in 
association with a combination of serotonergic drugs; NMS, bradykinesia and lead pipe 
rigidity versus SS, hyperkinesias and clonus; and NMS, an idiosyncratic reaction to 
therapeutic dosages versus SS, a manifestation of toxicity (usually to a combination of 
drugs) to which everyone is liable. The differential diagnosis between SS and NMS can be 
further complicated when atypical antipsychotics are included in the prescription, 
because some of atypical antipsychotics are 5-HT1A receptor agonist by themselves 
(Odagaki, 2009).  
3.5 Pathophysiology 
It has been well accepted that excess serotonergic signal transduction in CNS, resulting 
mostly from increase in serotonin concentrations by several mechanisms, explains most, if 
not all, of the clinical features of ST or SS. However, it should be noticed that much of our 
understanding of the pathophysiology of SS derives from preclinical data. As indicated by 
Isbister & Buckley (2005), there is no evidence that serotonin behavioral syndrome defined 
in experimental behavioral pharmacology and ST/SS described in clinical medicine are even 
similar in terms of phenomenology or underlying mechanisms. The significant confusion in 
the literature has been created especially as to the pathophysiological roles of 5-HT1A and 5-
HT2A receptors implicated in SS. As discussed earlier (Isbister & Buckley, 2005; Odagaki, 
2009), the possible important roles of 5-HT2A receptors in pathogenesis of SS, in particular 
the severe cases with hyperthermia and/or muscle hypertonicity, should be taken into 
consideration. 
3.6 Treatment 
Of most importance are prompt recognition of toxicity and discontinuation of offending 
medications in management of ST. Most cases of ST, even if represented as a full-blown 
form of SS, are self-limiting, if medications are withdrawn promptly at their early stages and 
no complications occur. In some patients, however, life-threatening severe toxicity can 
develop. Severe toxicity is more likely in patients ingesting overdosed serotonergic agent(s) 
or at least two drugs with different mechanisms of action, with combinations of SSRIs and a 
MAOI being the most common (Isbister & Buckley, 2005). The Toxic Exposure Surveillance 
System in the United States reported over 100 deaths related to ingestion of SSRIs in 2004 
(Watson et al., 2005), though it was unclear whether all of these cases could be diagnosed 
clinically as SS. 
Most cases with ST can be managed by means of supportive care with intravenous fluids as 
well as with symptomatic therapies according to the clinical features and severity, e.g., 
aggressive external cooling for hyperthermia, benzodiazepines or barbiturates for seizures, 
and benzodiazepines for muscle rigidity, myoclonus, or agitation. The use of 
nondepolarizing paralyzing agents under mechanical ventilation is indicated when muscle 
rigidity remains refractory to benzodiazepines (Mills, 1995; Isbister & Buckley, 2005). 
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In the severe SS cases, more specific therapy may be considered. The most commonly used 
drugs have been methysergide, cyproheptadine, and chlorpromazine (Mills, 1995; Gillman, 
1999). However, the SS cases reported to be successfully treated with these medications are 
all anecdotal, with randomized controlled trials lacking. Based on the pharmacological 
properties of these drugs as well as on the experimental results using an animal model of SS 
(Nisijima et al., 2007), Isbister & Buckley (2005) suggested that nonselective 5-HT2 
antagonists such as ketanserin or selective 5-HT2A antagonists such as atypical 
antipsychotics may be effective for the treatment of SS. The use of atypical antipsychotics for 
treating SS is, however, not recommended, at least when NMS is not clearly excluded. There 
has been a report of the patient who showed SS caused by sertraline intake and 
consecutively NMS induced by risperidone (J.-M. Kim et al., 2007). 
4. SSRI discontinuation syndrome 
4.1 Background 
Pharmacotherapy for mood and anxiety disorders has been dramatically changed during 
the last two decades, especially with an expanding increase in use of SSRIs for the treatment 
of broad spectrum including depression, varied types of anxiety, eating, obsessive-
compulsive, and impulse-control disorders. In parallel with the wide-spread use of SSRIs, 
reports of SSRI discontinuation syndrome have been increased. As described below, it 
sometimes involves alterations in mental function, which may be interpreted as a relapse or 
worsening of the original disorders. This is the reason why the author intends to summarize 
the syndrome in brief here in this chapter. 
Antidepressant discontinuation syndrome (Dilsaver & Greden, 1984; Dilsaver et al., 1987; 
Lejoyeux et al., 1996) had been well identified since first reported for imipramine in 1959 
(Andersen & Kristiansen, 1959; Mann & MacPherson, 1959, as cited in these three reviews). 
The initial SSRI discontinuation syndrome was described for fluoxetine in 1988 (Cooper, 
1988), and subsequent many case reports and review articles indicated it can develop for all 
SSRIs. Some researchers include discontinuation symptoms related with other 
antidepressants than SSRIs, such as venlafaxine, nefazodone, trazodone, and mirtazapine, in 
the same syndrome (Schatzberg et al., 1997a; Tamam & Ozpoyraz, 2002). 
Although the terms discontinuation and withdrawal are sometimes used interchangeably, the 
latter should be avoided for the patients treated with antidepressants including SSRIs, since 
these drugs are, unlike opiates or sedative-hypnotics, non-addictive (Schatzberg et al., 
1997b; Shelton, 2006).  
4.2 Clinical features and diagnosis 
Schatzberg et al. (1997b) raised the hallmark features of SRI discontinuation syndrome, as 
shown in Table 7. The clinical symptoms of SSRI discontinuation syndrome resemble those 
of TCA discontinuation syndrome, which had been classified into the following five main 
categories (Dilsaver & Greden, 1984; Dilsaver et al., 1987; Lejoyeux et al., 1996; Haddad, 
1997; Taman & Ozpoyraz, 2002): (1) gastrointestinal and general somatic distress symptoms, 
e.g., anxiety, agitation, muscle tension, nervousness, flu-like symptoms (fatigue, headache, 
sweating, myalgia), lethargy, nausea, vomiting, asthenia; (2) sleep disturbances, such as 
insomnia and excessive and vivid dreams, (3) movement disorders, e.g., akathisia, 
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parkinsonism, unsteady gait, abnormal movements of mouth and tongue; (4) behavioral 
activation, such as panic attacks, delirium, mania or hypomania; and (5) miscellaneous 
symptoms, such as cardiac arrhythmias. In the case of SSRI discontinuation syndrome, 
however, cardiac arrhythmias are seldom or never observed (Haddad, 1998), probably due 
to their minimal or negligible antimuscarinic activity and cardiotoxicity. In addition to, and 
probably overlapped with, these symptoms commonly seen in TCA discontinuation 
syndrome, further three symptom clusters are described to follow SSRI termination, i.e., (1) 
problems with balance (dizziness, ataxia, vertigo); (2) sensory abnormalities (electric shock-
like sensations, paresthesia); and (3) aggressive and impulsive behavior (suicide attempts, 
hoarding during discontinuation) (Haddad, 1998). The proposed diagnostic criteria (Black et 
al., 2000) are shown in Table 8. 
Hall mark features of SRI discontinuation syndrome
1. Not attributable to other causes
2. Emergent upon abrupt discontinuation, intermittent noncompliance (e.g., missed 
doses, drug holidays), and less frequently, with dose reduction 
3. Generally mild and short-lived
4. Self-limiting but can be distressing
5. Rapidly reversed by the reintroduction of the original medication or the 
substitution of one that is pharmacologically similar 
6. Minimized by slow tapering or by using a drug with an extended half-life 
Table 7. Hall mark features of SRI discontinuation syndrome (Schatzberg et al., 1997b) 
Criterion Description
A Discontinuation of or reduction in dose of an SSRI after a period of use of at 
least 1 month 
B Two (or more) of the following, developing within 1 to 7 days of criterion A 
  Dizziness, light-headedness, vertigo or feeling faint








  Nausea and/or emesis
  Tremor
  Visual disturbances
C The symptoms in Criterion B cause clinically significant distress or 
impairment in social, occupational or important areas of functioning 
D The symptoms are not due to a general medical condition and are not better 
accounted for by recurrence of symptoms of the mental disorder for which 
the SSRI was originally prescribed, or by concurrent discontinuation (or 
reduction in use) of another psychoactive substance 
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SSRI discontinuation symptoms occur within 1 to 3 days subsequent to cessation of 
treatment or reduction in dose in the majority of cases (Black et al., 2000). In the case of 
fluoxetine, however, the symptoms can develop slower (Einbinder, 1995) due to its longer 
half-life compared with those of other SSRIs (Table 9). In most cases, the syndrome is mild 
and short-lived, with persisting duration usually not exceeding 1-3 weeks even if untreated 
(Coupland et al., 1996; Black et al., 2000). 
SSRI Half-life (Haddad, 1998) Half-life 
(Schatzberg et al., 1997a)  Single dose Multiple dose
Paroxetine 10 h 21 h 21 h 
Fluvoxamine 15 h 22 h 15 h 
Sertraline 26 h 26 h 26 h (66 h)∗ 
Citalopram 33 h 33 h
Fluoxetine 1.9 d 5.7d (7-15d)∗ 84 h (4-16 d)∗ 
∗Half-life for an active metabolite shown in parentheses. h=hours, d=days. 
Table 9. Half-lives of SSRIs (Schatzberg et al., 1997a; Haddad, 1998) 
The half-life of the SSRI and its active metabolite (Table 9) probably contributes also to the 
likelihood of developing discontinuation syndrome for each drug. As anticipated from the 
half-life, the discontinuation events are more frequently and profoundly experienced with 
SSRIs with shorter half-life, in particular with paroxetine, and least often with fluoxetine 
that has the longest half-life (Coupland et al., 1996; Price et al., 1996; Rosenbaum et al., 1998). 
4.3 Pathophysiology 
As indicated above, plasma half-life of the SSRI is apparently one of the most important 
factors for occurrence of discontinuation syndrome, and thus the pathogenic mechanisms 
underlying SSRI discontinuation syndrome have to be supposed in accordance with this 
fact. The simplest and most plausible explanation is an abrupt decrease in availability of 
synaptic serotonin caused by withdrawal or decrease of the SSRI, in the face of down-
regulated serotonin receptors as a result of synaptic adaptation to long-term SSRI treatment 
(Schatzberg et al., 1997a). 
In addition to this hypothesis, Schatzberg et al. (1997a) also raised the following three other 
mechanisms that possibly contribute to some clinical features of the syndrome: (1) 
secondary effects on other neurotransmitters than serotonin; (2) individual genetic or 
psychological differences; and (3) cholinergic rebound. 
4.4 Clinical implications and treatment 
Rosenbaum & Zajecka (1997) indicated practical strategies for management of SRI 
discontinuation syndrome as follows: (1) reassuring patients that the symptoms are likely to 
be short-lived and mild; (2) for severe and distressing symptoms, the dosage of the drug 
prescribed immediately before the onset of discontinuation symptoms should be 
reinstituted and the rate of taper should be slowed; (3) all SRIs, with the exception of 
fluoxetine, should be gradually tapered; and (4) using or switching to agents with an 
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The rate of tapering of the drug should depend on its pharmacokinetic and pharmacological 
profile, current dose, duration of treatment, other drugs concomitantly prescribed, the 
patient’s physical, psychological, and social situations, and so on. Physicians who prescribe 
SSRIs should be aware of the risk of this syndrome at the termination of treatment, or even 
during maintenance therapy with a fixed dose. Missing even as few as two doses of a SSRI 
with a short half-life, which is very often unreported to the physician, might lead to the 
discontinuation symptoms (Kaplan, 1997). It should be noted some discontinuation 
symptoms, e.g., anxiety, irritability, fatigue, and insomnia, are sometimes hardly 
distinguishable from those of a relapse or recurrence of the primary affective or anxiety 
disorders. 
5. Other encephalopathic symptoms associated with psychotropic drugs 
5.1 Hyponatremic encephalopathy 
Hyponatremia is among the most common electrolyte abnormalities encountered in clinical 
practice (Upadhyay et al., 2006, 2009), and it is not rare to experience encephalopathic 
symptoms such as seizures and altered consciousness due to severe hyponatremia, usually 
in association with psychogenic polydipsia (Dundas et al., 2007) or self-induced water 
intoxication (Vieweg et al., 1987; Riggs et al., 1991), in psychiatric patients treated with 
psychotropic drugs (de Leon et al., 1994). 
Clinical severity of hyponatremia is related not only to the absolute level of serum sodium 
concentration, but also to the rate at which hyponatremia develops. Premonitory or early 
symptoms include nausea, vomiting, anorexia, disorientation, headache, fatigue, weakness, 
irritability, lethargy, confusion, and muscle cramps. Acute severe hyponatremia causes 
cerebral edema that can lead to coma, irreversible neurologic damage, and supratentorial 
cerebral herniation resulting in respiratory arrest from brain stem compression and death. In 
contrast, patients with chronic hyponatremia are often asymptomatic, even with serum 
sodium level as low as 120 mEq/L (Adroqué, 2005). As hyponatremia progresses, above-
mentioned premonitory, nonspecific symptoms are followed by neuropsychiatric symptoms 
such as seizures, hemiplegia, dysarthria, hallucinations, tremor, and coma. Patients may 
demonstrate an impaired response to verbal and painful stimuli, and exhibit bizarre 
behavior or experience auditory or visual hallucinations (Fraser & Arieff, 1997). These 
psychiatric symptoms may mimic the manifestations of primary psychiatric disorders such 
as schizophrenia, and thus clinicians should be careful not to be misled into a judgment that 
the primary disorder is exacerbated. It also should be considered that compulsive water 
consumption in the late afternoon and evening may impair mental status and further 
exacerbate psychiatric symptoms (Siegel, 2008). 
Although hyponatremia is derived from a variety of etiologies and classified into several 
types according to plasma and urine osmolarity as well as the volume of the total body 
water (Reddy & Mooradian, 2009), hyponatremic encephalopathy in psychiatric patients is 
usually the so-called polydipsia-hyponatremia syndrome (psychogenic polydipsia) with 
hypotonic plasma osmolarity and euvolemic status of the total body water. However, 
compulsive water drinking alone is usually not sufficient to induce marked hyponatremia, 
because the normal kidney should theoretically be able to excrete water in excess of 20 liters 
per day and most patients actually ingest less water than that theoretically required (Vieweg 
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et al., 1987; Fraser & Arieff, 1997). As demonstrated by Goldman et al. (1988), the patients 
with polydipsia and hyponatremia are accompanied with impaired maximal urinary 
dilution and free-water clearance in response to water loading, suggesting renal abnormally 
enhanced sensitivity to low concentrations of arginine vasopressin (AVP). They also showed 
that the patients with a history of polydipsia and hyponatremia demonstrated a higher 
serum AVP levels as well as greater thirst independent of their serum osmolarity after 
receiving an infusion of hypertonic saline, suggestive of a downward shift in the threshold 
for AVP release and defect of osmoregulation of thirst, respectively (Siegel, 2008). 
Most psychiatric patients with polydipsia-hyponatremia syndrome are thus associated with 
maladapted water and electrolyte homeostasis sustained principally by the action of 
neurohypophyseal antidiuretic hormone AVP. It has been demonstrated that lots of 
psychotropic drugs including antipsychotics, antidepressants, and anticonvulsants, can 
cause syndrome of inappropriate antidiuretic hormone secretion (SIADH) (Spigset & 
Hedenmalm, 1995; Bhuvaneswar et al., 2009; Reddy & Mooradian, 2009), and that 
antipsychotic-induced hyponatremia is most likely a result of SIADH (Meulendijks, 2010). 
Vieweg et al. (1987) also postulated that the syndrome of self-induced water intoxication 
and psychosis (SIWIP) was a subcategory of SIADH, with hypoosmolality and 
hyponatremia induced synergistically by polydipsia and released AVP, both of which were 
stimulated by psychosis. In the schizophrenic patients with polydipsia-hyponatremia 
syndrome, plasma AVP levels were shown to rise sharply after the pharmacological 
induction of psychotic symptoms with methylphenidate (Goldman et al., 1997). This 
mechanism may underlie the episodic escalation of polydipsia observed in psychotically 
exacerbated patients [psychosis, intermittent hyponatremia, and polydipsia (PIP) syndrome 
(Leadbetter et al., 1994)], which sometimes result in severe, life-threatening hyponatremic 
encephalopathy (Vieweg et al., 1985). 
Treatment of hyponatremic symptoms in psychiatric patients depends on their severity as 
well as the rate of development (Siegel, 2008). Acute severe hyponatremic encephalopathy 
could be life-threatening, which thus has to be treated as an emergency with hypertonic 
saline to prevent cerebral edema. On the other hand, chronic hyponatremia associated with 
psychogenic polydipsia is optimally managed with behavioral treatments including fluid 
restriction (Dundas et al., 2007) and removal of, if identified, underlying causes. Careful 
monitoring of diurnal body weight change for the PIP syndrome patients is useful to 
recognize hyponatremic episodes at an earlier stage and prevent sequelae due to severe 
hyponatremic encephalopathy (Leadbetter et al., 1994). In any case, osmotic demyelination, 
such as central pontine myelinolysis, possibly associated with overaggressive correction of 
serum sodium concentrations (more than 10 mmol/L in 24 hours, 18 mmol/L in 48 hours, 
and 20 mmol/L in 72 hours), should be avoided (Sterns et al., 2009). Specific 
pharmacological treatment with democlocycline or AVP receptor antagonists (aquaretics) 
for chronic hyponatremia in psychiatric patients may become standardized in the near 
future (Siegel, 2008). 
5.2 Valproate-induced hyperammonemic encephalopathy 
It has been known that valproic acid occasionally induces hyperammonemic 
encephalopathy in patients with otherwise normal hepatic function (Carr & Shrewsbury, 
2007; Marie-José, 2007). In most cases, encephalopathic symptoms appear in a few days after 
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initiation of valproate therapy, with exceptional case reports with onset after longer 
therapeutic periods for several months or years. There remains controversy as to whether 
symptoms have any relationship to daily dose or plasma concentration of valproic acid. In a 
prospective study, the significantly higher prevalence of asymptomatic hyperammonemia 
was found in the psychiatric patients treated with valproate than in the control, and there 
was a positive correlation between serum valproic acid concentrations and ammonia levels 
(Raja & Azzoni, 2002). Nevertheless, it should be noted that many cases with symptomatic 
encephalopathic symptoms reported up to date have serum valproic acid concentrations 
within therapeutic range (Carr & Shrewsbury, 2007; Marie-José, 2007). 
5.3 Transient splenial lesion of the corpus callosum 
Since several antiepileptic drugs have been widely prescribed as effective mood stabilizers 
in psychiatric practice (Grunze, 2010), all psychiatrists should be familiar with adverse 
phenomena associated with them. With widespread use of magnetic resonance imaging 
(MRI), a characteristic discrete focal lesion limited to the central area of the splenium of the 
corpus callosum has been recognized to occur in epileptic patients receiving antiepileptic 
drugs (S.S. Kim et al., 1999; Polster et al., 2001). Although the pathophysiological 
mechanisms of this lesion are still obscure, antiepileptics appear to be implicated as 
pathogenetic or triggering factors at least in some cases. Indeed, the same lesion has been 
reported also in the non-epileptic patients treated with antiepileptic drugs (Maeda et al., 
2003; Honda et al., 2006). Some patients developed the lesion on treatment with antiepileptic 
drugs (Kim et al., 1999; Polster et al., 2001; Maeda et al., 2003), while others subsequent to 
withdrawal of them (Polster et al., 2001; Gürtler et al., 2005; Honda et al., 2006). 
The lesion is usually detected accidentally by MRI, accompanied with no apparent clinical 
signs and symptoms. It is characterized with an isolated oval-shaped abnormal signal in 
MRI located in the central area of the splenium, no enhancement on post-contrast MRI, and 
complete reversibility without specific treatment. In consideration of its benign outcome, 
unnecessary invasive examination and therapeutic intervention should be avoided (Maeda 
et al., 2003). 
5.4 Miscellaneous 
Acute onset alterations in CNS function are derived from a variety of etiological factors. 
When specific pathogenetic processes directly invading the brain (e.g., vascular, infectious, 
and neoplastic diseases) are ruled out, other diffuse, multifocal, or metabolic causes should 
be considered (Posner et al., 2007). If treated with psychotropic drugs, the possibility of 
direct or indirect contribution of these chemicals to the pathophysiological status should be 
always evaluated with caution. The SIADH associated with psychotropic drugs and 
valproate-induced hyperammonemia, both of which have been described above, exemplify 
such implication. In addition, many psychotropic drugs, especially antidepressants and 
antipsychotics, have been shown to possess ability to reduce seizure threshold and to 
provoke epileptic seizures (Alldredge, 1999; Pisani et al., 2002). Antipsychotics, in particular 
atypical antipsychotics such as clozapine and olanzapine, are reported to be associated with 
an increased risk of obesity, diabetes, and metabolic syndrome (Scheen & De Hert, 2007; 
Smith et al., 2008) and in the worse case it can result in fatal hyperglycemic encephalopathy 
(Koller & Doraiswamy, 2002; Wehring et al., 2003). Lithium, a widely used mood stabilizer, 
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increases the risk of hypothyroidism, which can range from subclinical to life-threatening 
myxedema coma (Bhuvaneswar et al., 2009; Thomas et al., 2010). A case of Hashimoto’s 
encephalopathy possibly induced by lithium was also reported (Nagamine et al., 2008). 
6. Concluding remarks 
In these two decades, pharmacotherapy with psychotropic drugs for mentally ill patients 
has been dramatically changed. Classical prototypal antipsychotics, such as chlorpromazine 
and haloperidol, have been replaced with atypical antipsychotic drugs for the treatment of 
psychotic patients. As for the pharmacotherapy for mood disorders, total antidepressant 
prescribing has increased, especially in 1990s with exponential increase in prescriptions of 
SSRIs (Donoghue, 1998; Middleton, et al., 2001). This remarkable rise in SSRIs prescribing 
experienced in the United Kingdom may be attributable, in part, to the Defeat Depression 
Campaign (Paykel et al., 1997), which was undertaken from 1992 to 1996. However, the 
similar trends in antidepressant prescriptions have also been observed in all other 
developed countries worldwide. The vigorous marketing promoted by pharmaceutical 
companies probably contributed to the overwhelming spread of SSRIs in 1990s to a great 
extent (McHenry, 2005). In addition, SSRIs have been more and more prescribed not only for 
depression but also for a number of other psychiatric diagnoses such as anxiety, eating, 
impulse-control, and personality disorders. Many antiepileptic drugs are also prescribed 
generally for psychiatric patients in anticipation of their mood stabilizing effects. 
In general, the newly developed psychotropic drugs are believed to be safer and more 
tolerable than older drugs. The apparent lowered risk of adverse effects of novel drugs may 
facilitate the clinician’s attitude for prescribing these psychotropic drugs automatically, and 
sometimes indiscreetly. However, there is no efficacious drug without adverse side effects. 
All clinicians who have an occasion to prescribe psychotropic drugs, or to see the patients 
treated with them, should be familiar with adverse symptoms associated with them. 
This chapter focuses on the adverse effects of psychotropic drugs involving altered CNS 
function. Although nonspecific CNS reaction due to overdosed psychotropic drugs has not 
been included, it should be always taken into consideration when the patients treated with 
psychotropic drugs exhibit inexplicable CNS symptoms. Lithium-induced toxic 
encephalopathy has been reported to occur even when serum lithium levels are kept within 
a therapeutic range (Sheean, 1991). When adverse effects on CNS function are presented 
apparently as psychiatric symptoms, these should not be misdiagnosed as exacerbation of 
the primary psychiatric disorder. Such misjudgment may lead to the clinical decision to 
increase the offending drugs or to add other kinds of psychotropic drugs, which could 
further complicate matters and delay appropriate intervention. Even in the case of the 
idiosyncratic adverse effects such as NMS, the most efficacious way to abort the syndrome 
without serious sequelae should be early recognition of, and prompt appropriate 
intervention in, the clinical symptoms at the incipient stage. 
Pharmacotherapy becomes meaningfully efficacious only when it is considered in the whole 
therapeutic framework and associated synergistically with other psychosocial therapies. In 
general, most psychotropic drugs have only limited therapeutic effects, which never cure 
the psychiatric diseases themselves but relieve the symptoms partially. The efficacy of SSRIs 
in depressed patients over placebo has been shown to be minimal, if any, by recent meta-
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analyses (Moncrieff & Kirsch, 2005). While it is true that pharmacotherapy bring enormous 
benefit to some patients, I have also been aware of many cases at a disadvantage associated 
with thoughtless or unnecessary use of psychotropic drugs. The prudent and conscientious 
decision-making for pharmacotherapy in consideration of the quality of life of the 
individual patient is highly warranted. 
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